Older child/young adult acute lymphoblastic leukemia (ALL) outcomes.
| Country . | Nat’l Trial . | Age in Years . | # Pts . | CR (%) . | 5-Yr EFS (%) . | Ref. . |
|---|---|---|---|---|---|---|
| Abbreviations: CR, complete remission; EFS, event-free survival; P, pediatric protocol; A, adult protocol | ||||||
| * 6-yr EFS | ||||||
| ** 2-year overall survival | ||||||
| US: | CCG (P) | 16–21 | 196 | 96 | 64* | 4 |
| CALGB (A) | 103 | 93 | 38* | |||
| France: | FRALLE 93 (P) | 15–20 | 77 | 94 | 67 | 5 |
| LALA94 (A) | 100 | 83 | 41 | |||
| Holland: | DCOG (P) | 15–18 | 47 | 98 | 69 | 6 |
| HVON (A) | 44 | 91 | 34 | |||
| UK: | ALL97 (P) | 15–17 | 61 | 98 | 65 | 7 |
| UKALLXII (A) | 67 | 94 | 49 | |||
| Italy: | AIEOP (P) | 14–18 | 150 | 94 | 80** | 8 |
| Gimema (A) | 95 | 89 | 71** | |||
| Country . | Nat’l Trial . | Age in Years . | # Pts . | CR (%) . | 5-Yr EFS (%) . | Ref. . |
|---|---|---|---|---|---|---|
| Abbreviations: CR, complete remission; EFS, event-free survival; P, pediatric protocol; A, adult protocol | ||||||
| * 6-yr EFS | ||||||
| ** 2-year overall survival | ||||||
| US: | CCG (P) | 16–21 | 196 | 96 | 64* | 4 |
| CALGB (A) | 103 | 93 | 38* | |||
| France: | FRALLE 93 (P) | 15–20 | 77 | 94 | 67 | 5 |
| LALA94 (A) | 100 | 83 | 41 | |||
| Holland: | DCOG (P) | 15–18 | 47 | 98 | 69 | 6 |
| HVON (A) | 44 | 91 | 34 | |||
| UK: | ALL97 (P) | 15–17 | 61 | 98 | 65 | 7 |
| UKALLXII (A) | 67 | 94 | 49 | |||
| Italy: | AIEOP (P) | 14–18 | 150 | 94 | 80** | 8 |
| Gimema (A) | 95 | 89 | 71** | |||